Drug Trial Radar · NCT03315130
Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis
Last checked: Nov 20, 2026Latest source record: Jul 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Actual
Start
Oct 11, 2017
Primary completion
Dec 10, 2018
Study completion Nov 19, 2020
Sponsor
- Lead sponsor
- Ra PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Oct 19, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with generalized Myasthenia Gravis (gMG). Subjects will be randomized in a 1:1:1 ratio to receive daily SC doses of 0.1 mg/kg RA101495, 0.3 mg/kg RA101495, or matching placebo for 12 weeks.
Conditions
- Generalized Myasthenia Gravis
Interventions
zilucoplan (RA101495)Drug
Daily subcutaneous (SC) injection
PlaceboDrug
Daily subcutaneous (SC) injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Main Portion: Change From Baseline to Week 12 in Quantitative Myasthenia Gravis (QMG) ScoreTime frame: From Baseline to Week 12
Locations
30 sites in 2 countries. Site status is shown where the registry gives one.
Diagnostic and Medical Clinic - Mobile
Mobile, Alabama
The Research Center of Southern California
Carlsbad, California
UCLA Medical Center
Los Angeles, California
University of California Irvine Health ALS and Neuromuscular Center
Orange, California
Yale University
New Haven, Connecticut
George Washington University
Washington D.C., District of Columbia
University of Florida
Jacksonville, Florida
University of South Florida
Tampa, Florida
Rush University Medical Center
Chicago, Illinois
University of Kansas Medical Center
Kansas City, Kansas
University of Maryland
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Lahey Hospital and Medical Center
Burlington, Massachusetts
Wayne State University
Detroit, Michigan
Michigan State University
East Lansing, Michigan
University of Buffalo
Buffalo, New York
Hospital for Special Surgery
New York, New York
Mount Sinai Hospital
New York, New York
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Ohio State University
Columbus, Ohio
Allegheny Neurological Associates
Pittsburgh, Pennsylvania
Wesley Neurology Clinic
Cordova, Tennessee
University of Texas Southwestern
Dallas, Texas
University of Utah
Salt Lake City, Utah
University of Vermont
Burlington, Vermont
Center for Neurological Disorders
Milwaukee, Wisconsin
University of Alberta Hospital
Edmonton, Alberta, Canada
London Health Sciences Centre University Hospital
London, Ontario, Canada
Toronto General Hospital
Toronto, Ontario, Canada
Montreal Neurological Institute and Hospital
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.